[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:secretory-phospholipase-a2-receptor":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Secretory Phospholipase A2 Receptor",6,[7,15,21,28,34,40],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07571746","A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease",[11],"Phase 2","RECRUITING","2026-08-26T02:18:39.640967Z","2026-05-13T02:55:06.777799Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT07157787","Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)",[11],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:29.336655Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT05696613","A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy",[25],"Phase 3","2026-08-26T02:14:59.425132Z","2026-05-05T02:43:27.998701Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT06962800","A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)",[25],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:27.513583Z",{"nct_id":35,"title":36,"phases":37,"status":12,"updated_at":38,"content_modified":39},"NCT03949855","Belimumab With Rituximab for Primary Membranous Nephropathy",[11],"2026-08-26T02:15:00.557154Z","2026-04-29T02:57:57.088720Z",{"nct_id":41,"title":42,"phases":43,"status":12,"updated_at":44,"content_modified":45},"NCT06983028","Atacicept in Multiple Glomerular Diseases",[11],"2026-08-26T02:17:42.501124Z","2026-07-05T05:32:16.725563Z"]